Ambrx Biopharma Current Ratio 2020-2023 | AMAM
Ambrx Biopharma current ratio from 2020 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Ambrx Biopharma Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2023-03-31 |
$0.16B |
$0.02B |
10.13 |
| 2022-12-31 |
$0.09B |
$0.02B |
5.44 |
| 2022-06-30 |
$0.12B |
$0.03B |
4.70 |
| 2022-03-31 |
$0.00B |
|
0.00 |
| 2021-12-31 |
$0.18B |
$0.03B |
7.19 |
| 2021-06-30 |
$0.17B |
$0.02B |
9.90 |
| 2020-12-31 |
$0.09B |
$0.01B |
7.02 |
| 2019-12-31 |
$0.02B |
$0.02B |
1.22 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.824B |
$0.007B |
|
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
|
